Phospho-FACS: A powerful tool for exploring intracellular transduction cascades;Le phospho-FACS: Un outil puissant d'exploration des cascades de transduction intracellulaires

Revue des Maladies Respiratoires

Volumn 24, Issue 8, 2007, Pages 955-964

  Gernez, Y ^a   Herzenberg, L A ^a,a   Tirouvanziam, R ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Inflammation; Kinases; Signal transduction

Indexed keywords

BCR ABL PROTEIN; CALCIUM ION; CD161 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOKINE; DNA; EPITOPE; FOCAL ADHESION KINASE 2; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE SYK; STAT1 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; STEM CELL FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; UNINDEXED DRUG;

CLINICAL RESEARCH; CYTOLOGY; CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; METABOLITE; MOLECULAR BIOLOGY; PHOSPHORYLATION; REVIEW;

EID: 36248945698     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0761-8425(07)92761-8     Document Type: Article

References (32)

1. Herzenberg LA: FACS innovation: a view from Stanford. Clin Invest Med 2004; 27: 240-52.
2. Herzenberg LA, Tung J, Moore WA, Herzenberg LA, Parks DR: Interpreting flow cytometry data: a guide for the perplexed. Nat Immunol 2006; 7: 681-5.
3. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg, LA: High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A 2006; 103: 4628-33.
4. Tirouvanziam R, Davidson CJ, Lipsick JS, Herzenberg LA: Fluorescence-activated cell sorting (FACS) of Drosophila hemocytes reveals important functional similarities to mammalian leukocytes. Proc Natl Acad Sci U S A 2004; 101: 2912-7.
5. Perez OD, Krutzik PO, Nolan GP: Flow cytometric analysis of kinase signaling cascades. Methods Mol Biol 2004; 263: 67-94.
6. Dunn DA: Mining the human "kinome". Drug Discov Today 2002; 7: 1121-3.
7. Okutani D, Lodyga M, Han B, Liu M: Src protein tyrosine kinase family and acute inflammatory responses. Am J Physiol Lung Cell Mol Physiol 2006; 291: L129-41.
8. Ferrajoli A, Faderl S, Ravandi F, Estrov Z: The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 2006; 6: 671-9.
9. Dong C, Davis RJ, Flavell RA: MAP kinases in the immune response. Annu Rev Immunol 2002; 20: 55-72.
10. Houslay MD: A RSK(y) relationship with promiscuous PKA. Sci STKE 2006; 2006: pe32.
11. Amaravadi R, Thompson CB: The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005; 115: 2618-24.
12. Strassheim D, Asehnoune K, Park JS, Kim JY, He Q, Richter D, Kuhn K, Mitra S, Abraham E: Phosphoinositide 3-kinase and Akt occupy central roles in inflammatory responses of Toll-like receptor 2-stimulated neutrophils. J Immunol 2004; 172: 5727-33.
13. Serova M, Ghoul A, Benhadji KA, Cvitkovic E, Faivre S, Calvo F, Lokiec F, Raymond E: Preclinical and clinical development of novel agents that target the protein kinase C family. Semin Oncol 2006; 33: 466-78.
14. Tonks NK: Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 2006; 7: 833-46.
15. Mustelin T, Vang T, Bottini N: Protein tyrosine phosphatases and the immune response. Nat Rev Immunol 2005; 5: 43-57.
16. Viatour P, Merville MP, Bours V, Chariot A: Phosphorylation of NF-kB and IkB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005; 30: 43-52.
17. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37: 19-24.
18. Baumgarth N, Roederer M: A practical approach to multicolor flow cytometry for immunophenotyping. J Immunol Methods 2000; 243: 77-97.
19. Tung JW, Parks DR, Moore WA, Herzenberg LA, Herzenberg LA: New approaches to fluorescence compensation and visualization of FACS data. Clin Immunol 2004; 110: 277-83.
20. Gernez Y, Conrad CK, Moss RB, Herzenberg LA, Tirouvanziam R: Single-cell phosphoepitope profiling in live blood and sputum neutrophils brings insights into CF inflammatory pathophysiology. Pediatr Pulmonol 2006; 41: 268.
21. Gernez Y, Tirouvanziam R, Nguyen KD, Herzenberg LA, Krensky AM, Nadeau KC: Asthma patients demonstrate characteristic patterns of phospho-STAT expression in CD4+CD161+ blood lymphocytes. Proc Am Thorac Soc 2007; 4: sous presse.
22. Blease K: Targeting kinases in asthma. Expert Opin Investig Drugs 2005; 14: 1213-20.
23. Arena S, Benvenuti S, Bardelli A: Genetic analysis of the kinome and phosphatome in cancer. Cell Mol Life Sci 2005; 62: 2092-9.
24. Tirouvanziam R: Neutrophilic inflammation as a major determinant in the progression of cystic fibrosis. Drug News Perspect 2006; 19: 609-14.
25. Umetsu DT, Dekruyff RH: The regulation of allergy and asthma. Immunol Rev 2006; 212: 238-55.
26. Takahashi T, Dejbakhsh-Jones S, Strober S: Expression of CD161 (NKR-P1A) defines subsets of human CD4 and CD8 T cells with different functional activities. J Immunol 2006; 176: 211-6.
27. Christodoulopoulos P, Cameron L, Nakamura Y, Lemiere C, Muro S, Dugas M, Boulet LP, Laviolette M, Olivenstein R, Hamid Q: TH2 cytokine-associated transcription factors in atopic and nonatopic asthma: evidence for differential signal transducer and activator of transcription 6 expression. J Allergy Clin Immunol 2001; 107: 586-91.
28. Pernis AB, Rothman PB: JAK-STAT signaling in asthma. J Clin Invest 2002; 109: 1279-83.
29. Marshall J: Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 2006; 107: 1207-18.
30. Jabbour E, Cortes J, Kantarjian H: Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol 2006; 18: 578-83.
31. Arslan MA, Kutuk O, Basaga H: Protein kinases as drug targets in cancer. Curr Cancer Drug Targets 2006; 6: 623-34.
32. Knight ZA, Shokat KM: Features of selective kinase inhibitors. Chem Biol 2005; 12: 621-37.